All In Biotech

Drug Trial Radar · NCT01442727

Selenium in the Treatment of Arsenic Toxicity and Cancers

Selenite in the Detoxification of Arsenic and the Prevention of Arsenical Melanosis and Cancers Amongst Bangladeshi Arsenicosis Patients: A 48-week, Randomized, Double-blinded, Placebo-controlled Phase III Trial

Last checked: Nov 20, 2026Latest source record: Oct 7, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 819 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

819

Actual

Start

Dec 2006

Primary completion

Apr 2009

Study completion Apr 2009

Sponsor

Lead sponsor
Texas Tech UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI); American Cancer Society, Inc.
First posted
Sep 28, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Context: Approximately 100 million people throughout the world consume water contaminated with arsenic at levels above carcinogenic thresholds, including 40 million in Bangladesh alone, with up to one-fourth of deaths attributed to arsenic exposure in the worst-affected regions. There are no proven therapies for treating chronic arsenic toxicity or for preventing arsenical cancers. Selenium has been known to counter arsenic toxicity in a variety of animal models. The investigators have recently shown in animals and humans that this effect is mediated by the formation of \[(GS)2AsSe\]- , the seleno-bis(S-glutathionyl) arsinium ion, which is then rapidly excreted via the hepatobiliary system. Concurrently, two Phase II studies in China and Bangladesh have suggested clinical benefit to selenium supplementation in arsenicosis patients. Objective: To assess whether daily selenium supplementation counters arsenic toxicity in patients exposed to drinking water arsenic. If proven effective, selenium supplementation might be safely and cost-effectively implemented in the worst-affected localities.

Conditions

  • Arsenical Melanosis
  • Arsenical Keratosis
  • Arsenical Cancers
  • Arsenicosis
  • Arsenic Exposure
  • Arsenic Toxicity
  • Arsenic Poisoning

Interventions

  • sodium seleniteDrug

    200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast.

  • placeboDrug

    dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. changes in arsenical melanosisTime frame: 0 weeks (baseline), 24 weeks, and 48 weeks (end)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SETAC Trial Field Office

    Kalibari Town, Chandpur District, Bangladesh

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.